


Open Session of 23rd WHO Expert Committee on the Selection and Use of Essential Medicines

21st June 2021

Esteban Burrone
Medicines Patent Pool

Case study on Dolutegravir (DTG) and TLD Combination for HIV Treatment



List of medicines submitted for inclusion in 2021 that are still patent protected

Drug or class submitted	INN	Disease/Area	Primary patent expiry
Anti- PD1 immune checkpoints inhibitors	pembrolizumab [#]	non small cell lung cancer	2028
	nivolumab [#]		2026
	atezolizumab [#]		2029
	durvalumab [#]		2030
BRAK/MEK inhibitors	dabrafenib+ trametinib	metastatic melanoma	Dabrafenib: 2029 Trametinib: 2025
	vemurafenib+ cobimetinib		Vemurafenib: 2024-26 Cobimetinib: 2026
	encorafenib+ binimetinib		Encorafenib: 2029 Binimetinib: 2023
cefiderocol	cefiderocol	infections due to multi-drug resistant organisms	2029
Cyclin-dependent kinase (CDK) 4/6 inhibitors	palbociclib	HR+ /HER2- breast cancer	2023
	ribociclib		2027-29
	abemaciclib		2029
daratumumab	daratumumab [#]	multiple myeloma	2036
enzalutamide	enzalutamide	prostate cancer	2026-27
ibrutinib	ibrutinib	chronic lymphocytic leukaemia	2026 ^{\$}
zanubtrutinib	zanubtrutinib	chronic lymphocytic leukaemia & mantle cell lymphoma	2034
osimertinib	osimertinib mesylate	EGFR+ non small cell lung cancer	2032
pertuzumab	pertuzumab [#]	metastatic breast cancer	2020 (extension to 2025-6 in some countries)
Rabies monoclonal antibodies – rabies post-exposure prophylaxis	docaravimab [#] /miromavimab [#]	rabies post-exposure prophylaxis	2039
	rabishield [#]		2026
SGLT2 inhibitors	dapagliflozin	type 2 diabetes	2020-23
	canagliflozin		2024
	empagliflozin		2025
tislelizumab	tislelizumab [#]	urothelial carcinoma; Hodgkin lymphoma	2033

[#] biotherapeutics

^{\$} Note that a generic version was recently approved for use in the United States.

List of essential medicines for which MPP has licensing agreements with the patent holders

Medicine(s)	Indication in the EML/EMLc
Abacavir (paediatrics)	HIV
Abacavir/lamivudine	HIV
Atazanavir	HIV
Atazanavir/ritonavir	HIV
Daclatasvir	Hepatitis C (pangenotypic)
Darunavir*	HIV
Dolutegravir	HIV
Glecaprevir/pibrentasvir	Hepatitis C (pangenotypic)
Lopinavir/ritonavir	HIV
Raltegravir (paediatric)	HIV
Ritonavir	HIV
Tenofovir disoproxil fumarate	HIV/HIV Pre-exposure prophylaxis/Chronic Hepatitis B
Tenofovir disoproxil fumarate/emtricitabine	HIV/HIV Pre-exposure prophylaxis
Tenofovir disoproxil fumarate/emtricitabine/efavirenz	HIV
Tenofovir/lamivudine/efavirenz	HIV
Valganciclovir [#]	Cytomegaloviral retinitis

[#] Price agreement. * Licence did not cover all relevant patents on the product